Yale researchers uncover lung cancer resistance mechanism
A new Yale study has shown how lung cancer may develop resistance to therapy in some patients. Researchers at the School of Medicine have found that lung cancer cells may become resistant to a type of cancer therapy by disrupting patients’ normal immune response. The finding provides researchers with a molecular basis for understanding drug resistance in lung cancer. The study was published in the Cancer Discovery journal on Oct. 12. “Understanding the biology of acquired resistance to these therapies is really important because this knowledge will allow us to figure out what we need to do to treat resistant tumors,” said Katerina Politi, a professor in the School of Medicine’s Department of Pathology and the study’s senior author. “Knowledge of how tumors escape can also help us develop ideas for therapeutic approaches to prevent drug resistance.”
Study: Drug Has Long-term Survival Benefit for Some Lung Cancer Patients
“The response that we have seen from pembrolizumab, in a subset of patients years after treatment ended, is remarkable, especially since their chemotherapy had initially failed,” said Roy S. Herbst, M.D., Ph.D., chief of medical oncology at Yale Cancer Center and Smilow Cancer Hospital and director for translational research at Yale Cancer Center.
Make an informed decision about lung cancer screening
Lung cancer causes more deaths than any other cancer. In the United States, more men and women will die from lung cancer this year than from breast, colon, and prostate cancers combined. But there is good news: Doctors now know that low-dose radiation CT scans catch lung cancers early in certain high-risk groups, and can play a key role in preventing many lung cancer deaths.